U S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER: SOLEM=14

U S APPLICATION NO (If known, see 37 CFR 1 5): 10/019563

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY CLAIMED
PCT/SE00/01369	28 June 2000	29 June 1999

TITLE OF INVENTION: DEVICE AND METHOD FOR TREATMENT OF MITRAL INSUFFICIENCY

APPLICANT(S) FOR DO/EO/US: **Jan Otto SOLEM et al.**

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information

1. [X] This is a **FIRST** submission of items concerning a filing under 35 U.S C 371.
2. [ ] This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371
3. [X] This is an express request to begin national examination procedures (35 U S C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. [X] The US has been elected in a Demand by the expiration of 19 months from the priority date (PCT Article 31)
5. [X] A copy of the International Application as filed (35 U S C. 371(c)(2))
   a. [ ] is attached hereto (required only if not transmitted by the International Bureau).
   b [ ] has been communicated by the International Bureau
   c [X] is not required, as the application was filed in the United States Receiving Office (RO/US)
6. [ ] An English language translation of the International Application as filed (35 U S.C 371(c)(2)).
7. [X] Amendments to the claims of the International Application under PCT Article 19 (35 U S.C 371(c)(3))
   a [ ] are transmitted herewith (required only if not transmitted by the International Bureau).
   b [ ] have been communicated by the International Bureau.
   c [ ] have not been made; however, the time limit for making such amendments has NOT expired
   d [X] have not been made and will not be made
8. [ ] An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C 371(c)(3)).
9. [ ] An oath or declaration of the inventor(s) (35 U.S.C 371(c)(4)).
10. [ ] An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U S C 371(c)(5))

Items 11. to 16. below concern document(s) or information included:

11. [X] An Information Disclosure Statement under 37 CFR 1 97 and 1.98.
12. [ ] An Assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included
13. [X] A FIRST preliminary amendment.
    [ ] A SECOND or SUBSEQUENT preliminary amendment
14. [ ] A substitute specification.
15. [ ] A change of power of attorney and/or address letter
16. [X] Other items or information:
    [X] Courtesy copy of the International Application as filed
    [X] Courtesy copy of the first page of the International Publication (WO 01/00111)
    [X] Courtesy copy of the International Preliminary Examination Report There were no annexes
    [X] Formal drawings, 5 sheets, Figures 1-13.
    [X] Courtesy Copy of the International Search Report
    [X] Application Data Sheet

U.S. APPLICATION NO (If known, see 37 CFR 1 5)	International Application No	Attorney's Docket No
10/019563	PCT/SE00/01369	SOLEM=14

17. [xx] The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a)(1) –(5):

Neither international preliminary examination fee (37 CFR 1 482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO . **$1040.00**

International preliminary examination fee (37 CFR 1 482) not paid to USPTO but International Search Report prepared by the EPO or JPO..... **$890.00**

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1 445(a)(2)) paid to USPTO **$740.00**

International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... **$710.00**

International preliminary examination fee paid to USPTO (37 CFR 1 482) and all claims satisfied provisions of PCT Article 33(1)-(4).... .....**$100.00**

CALCULATIONS PTO USE ONLY

FEE VALUE ACCOUNTABILITY
DEPOSIT ACCOUNT NO.
02 4035
FEE CODE | VALUE FURNISHED
3

ENTER APPROPRIATE BASIC FEE AMOUNT =				$ 890.00
Surcharge of **$130.00** for furnishing the oath or declaration later than [ ] 20 [X] 30 months from the earliest claimed priority date (37 CFR 1 492(e)).				$ 130.00
Claims as Originally Presented	Number Filed	Number Extra	Rate	
Total Claims	13 - 20		X $18 00	$
Independent Claims	2 - 3		X $84.00	$
Multiple Dependent Claims (if applicable)			+$280 00	$ 280.00
TOTAL OF ABOVE CALCULATIONS =				$1,300.00
Claims After Post Filing Prel. Amend	Number Filed	Number Extra	Rate	
Total Claims	- 20		X $18 00	$
Independent Claims	- 3		X $84.00	$
TOTAL OF ABOVE CALCULATIONS =				$1,300.00
Reduction of ½ for filing by small entity, if applicable Applicant claims small entity status. See 37 CFR 1.27				$
SUBTOTAL =				$1,300.00
Processing fee of **$130.00** for furnishing the English translation later than [ ] 20 [ ] 30 months from the earliest claimed priority date (37 CFR 1 492(f))				$
TOTAL NATIONAL FEE =				$1,300.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3 28, 3 31) **$40.00** per property +				$
TOTAL FEES ENCLOSED =				$1,300.00
			Amount to be: refunded	$
			charged	$

a. [ ] A check in the amount of $_____ to cover the above fees is enclosed
b. [X] Credit Card Payment Form (PTO-2038), authorizing payment in the amount of $ 1,300.00, is attached.
c. [ ] Please charge my Deposit Account No. **02-4035** in the amount of $_____ to cover the above fees
A duplicate copy of this sheet is enclosed
d. [**XX**] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No **02-4035** A duplicate copy of this sheet is enclosed

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO

BROWDY AND NEIMARK, P.L.L.C.
624 NINTH STREET, N.W., SUITE 300
WASHINGTON, D.C. 20001
TEL: (202) 628-5197
FAX: (202) 737-3528

Date of this submission **December 31, 2001**

SIGNATURE
Roger L. Browdy
NAME
25,618
REGISTRATION NUMBER

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jan Otto SOLEM	)	Art Unit:
IA No.: PCT/SE00/01369	)	Washington, D.C.
IA Filed: June 28, 2000	)	
U.S. App. No.: (Not Yet Assigned)	)	December 31, 2001
National Filing Date: (Not Yet Received)	)	
For: DEVICE AND METHOD...	)	Docket No.: SOLEM=14

PRELIMINARY AMENDMENT

Honorable Commissioner for Patents and Trademarks
Washington, D.C. 20231

Sir:

Contemporaneous with the filing of this case, kindly amend as follows:

IN THE SPECIFICATION

After the title please insert the following paragraph:

--**REFERENCE TO RELATED APPLICATIONS**

The present application is the national stage under 35 U.S.C. 371 of international application PCT/SE00/01369, filed June 28, 2000 which designated the United States, and which international application was published under PCT Article 21(2) in the English language.

REMARKS

The above amendment to the specification is being made to insert reference to the PCT application of which the present case is a U.S. national stage.

Favorable consideration is earnestly solicited.

Respectfully submitted,
BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By: _____
Roger L. Browdy
Registration No. 25,618

RLB:wrd
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
F:\,A\Awap\Soleml4\PTO\Preliminary Amendment.doc

DEVICE AND METHOD FOR TREATMENT OF MITRAL INSUFFICIENCY

The present invention generally relates to a device and a method for treatment of mitral insufficiency and, more specifically, for treatment of dilatation of the mitral annulus.

Mitral insufficiency can result from several causes, such as ischemic disease, degenerative disease of the mitral apparatus, rheumatic fever, endocarditis, congenital heart disease and cardiomyopathy. The four major structural components of the mitral valve are the annulus, the two leaflets, the chordae and the papillary muscles. Any one or all of these in different combinations may be injured and create insufficiency. Annular dilatation is a major component in the pathology of mitral insufficiency regardless of cause. Moreover, many patients have a mitral insufficiency primarily or only due to posterior annular dilatation, since the annulus of the anterior leaflet does not dilatate because it is anchored to the fibrous skeleton of the base of the heart.

Studies of the natural history of mitral insufficiency have found that totally asymptomatic patients with severe mitral insufficiency usually progress to severe disability within five years. At present the treatment consists of either mitral valve replacements or repair, both methods requiring open heart surgery. Replacement can be performed with either mechanical or biological valves.

The mechanical valve carries the risk of thromboembolism and requires anticoagulation, with all its potential hazards, whereas biological prostheses suffer from limited durability. Another hazard with replacement is the risk of endocarditis. These risks and other valve related complications are greatly diminished with valve repair.

Mitral valve repair is theoretically possible if an essentially normal anterior leaflet is present. The basic four techniques of repair include the use of an annuloplasty ring, quadrangular segmental resection of diseased posterior leaflet, shortening of elongated chordae, and transposition of posterior leaflet chordae to the anterior leaflet.

Annuloplasty rings are needed to achieve a durable reduction of the annular dilatation. All the common rings are sutured along the posterior mitral leaflet adjacent to the mitral annulus in the left atrium. The Duran ring encircles the valve completely, whereas the others are open towards the anterior leaflet. The ring can either be rigid, like the original Carpentier ring, or flexible but non-elastic, like the Duran ring or the Cosgrove-Edwards ring.

Effective treatment of mitral insufficiency currently requires open-heart surgery, by the use of total cardiopulmonary by-pass, aortic cross-clamping and cardioplegic arrest.

To certain groups of patient, this is particular hazardous. Elderly patients, patients with a poor left ventricular function, renal disease, severe calcification of the aorta, previous cardiac surgery or other concomitant diseases, would in particular most likely benefit from a less invasive approach, even if repair is not complete. The current trend towards less invasive coronary artery surgery, without cardiopulmonary by-pass, as well as PTCA will also call for a development of a less invasive method for repair of the often concomitant mitral insufficiency.

Therefore, a first object of the present invention is to provide a device and a method for treatment of mitral insufficiency without the need for cardiopulmonary by-pass and opening of the chest and heart.

A second object of the invention is to provide reduction of the mitral annulus using less invasive surgery.

These and other objects are attained by a device as defined in the appended claim 1, and by a method as defined in the appended claim 7.

According to the present invention, a device for treatment of mitralis insufficiency comprises an elongate body having such dimensions as to be insertable into the coronary sinus and having two states, in a first state of which the elongate body has a shape that is adaptable to the shape of the coronary sinus, and to the second state of which the elongate body is transferable from the said first state assuming a reduced radius of curvature, whereby the radius of curvature of the coronary sinus is reduced as well as the circumference of the mitral valve annulus, when the elongate body is positioned in the coronary sinus.

Preferably, means are provided for the transfer of the elongate body to the second state by bending and/or shortening it from a larger radius of curvature to a smaller radius of curvature.

The transfer means may comprise means for bending and/or shortening the elongate body by a preferably asymmetric contraction thereof.

Further, the elongate body may comprise a memory material providing the transfer to the second state.

In a preferred embodiment, the elongate body may comprise a stent. In an alternative embodiment, the device according to the invention may comprise several stent sections and said bending and/or shortening means may comprise wires for shortening the distance between the stent sections.

According to a second aspect, a method of reducing the circumference of the mitral valve annulus comprises the steps of inserting an elongate body into the coronary sinus in the vicinity of the posterior leaflet of the

mitral valve, and then providing a bending and/or shortening of the elongate body when positioned in the coronary sinus so as to reduce the curvature of the coronary sinus and thereby reduce the circumference of the mitral valve annulus.

Thus, the present invention takes advantage of the position of the coronary sinus being close to the mitral annulus. This makes repair possible by the use of current catheter-guided techniques.

The coronary veins drain blood from the myocardium to the right atrium. The smaller veins drain blood directly into the atrial cavity, and the larger veins accompany the major arteries and run into the coronary sinus which substantially encircles the mitral orifice and annulus. It runs in the posterior atrioventricular groove, lying in the fatty tissue between the left atrial wall and the ventricular myocardium, before draining into the right atrium between the atrial septum and the post-Eustachian sinus.

In an adult, the course of the coronary sinus may approach within 5-15 mm of the medial attachment of the posterior leaflet of the mitral valve. Preliminary measurements performed at autopsies of adults of normal weight show similar results, with a distance of 5,3±0,6 mm at the medial attachment and about 10 mm at the lateral aspect of the posterior leaflet. The circumference of the coronary sinus was 18,3±2,9 mm at its ostium (giving a diameter of the posterior leaflet of 5,8±0,9 mm) and 9,7±0,6 mm along the lateral aspect of the posterior leaflet (corresponding to a diameter of 3,1±0,2 mm).

The invention will be better understood by the following description of preferred embodiments referring to the appended drawings, in which

Fig. 1 is a cross-sectional view of a part of a heart,

Figs 2 and 3 are schematic views of a first embodiment of a device according to the present invention,

Figs 4-6 are schematic views illustrating an instrument, which may be used when positioning the device shown in Figs 2 and 3 in the coronary sinus,

Fig. 7 is a partial, enlarged view of the first embodiment shown in Fig. 2.

Figs 8 and 9 are schematic views illustrating the positioning of the device of Figs 2 and 3 in the coronary sinus,

Figs 10 and 11 are schematic views illustrating the positioning of a second embodiment of the device according to the present invention in the coronary sinus, and

Figs 12 and 13 are schematic views illustrating the positioning of a third embodiment of the device according to the present invention in the coronary sinus.

Fig 1 is a cross-sectional view through the heart area of the posterior atrioventricular groove 1, which is filled with fatty tissue. It shows the posterior leaflet 2 of the mitral valve and the adjoining parts 3, 4 of the atrial myocardium and the ventricular myocardium. The coronary sinus 5 is shown close to the mitral annulus 6 and behind the attachment 7 of the posterior leaflet 2. Since the coronary sinus 5 substantially encircles the mitral annulus 6, a reduction of the radius of curvature of the bent coronary sinus 5 also will result in a diameter and circumference reduction of the mitral annulus 6.

The device of Fig. 2 comprises an elongate body 8 made of memory metal, e.g. Nitinol, or other similar material which has a memory of an original shape, illustrated in Fig. 3, and can be temporary forced into another shape, illustrated in Fig. 2. This elongate body 8 comprises one, two or more memory metal strings 9 of helical or other shape so as to fit together and be able

of permitting the movements described below. Along the elongate body 8 several hooks 10 are fastened so as to extend radially out therefrom. These hooks 10 are covered by a cover sheet 11 in Fig. 2.

The elongate body 8 is forced into a stretched or extended state by means of a stabilising instrument 12 shown in Fig. 4. This instrument 12 has two arms 13 at a distal end 14 of a rod 15 and a locking means 16 at a proximal end of the rod 15. The distance between the ends of the rod 15 corresponds to the desired length of the elongate body 8 when being inserted into the coronary sinus 5.

The arms 13 are free to move between the position shown in Fig. 4 and a position in alignment with the rod 15, as shown in Fig. 6. The locking means 16 has two locking knobs 17, which are pressed radially outwards from the rod 15 by two spring blades 18. Thus, the elongated body 8 can be pushed over the rod 15 of the stabilising instrument 12, then stretched between the arms 13 and the knobs 17, and finally locked in its stretched state on the stabilising instrument 12 between the arms 13 and the knobs 17, as illustrated in Fig. 5.

The rod 15 may be a metal wire which is relatively stiff between the distal end 14 and the locking means 16 but still so bendable that it will follow the shape of the coronary sinus 5. Proximally of the locking means 16 the metal wire of the stabilising instrument 11 is more pliable to be able to easily follow the bends of the veins.

The above-described elongate body 8 is positioned in the coronary sinus 5 in the following way:

An introduction sheet (not shown) of synthetic material may be used to get access to the venous system. Having reached access to the venous system, a long guiding wire (not shown) of metal is advanced through the introduction sheet and via the venous system to the coronary sinus 5. This guiding wire is provided with X-

ray distance markers so that the position of the guiding wire in the coronary sinus 5 may be monitored.

The elongate body 8 is locked onto the stabilising instrument 12, as shown in Fig. 5, and introduced into the long cover sheet 11 of synthetic material. This aggregate is then pushed through the introduction sheet and the venous system to the coronary sinus 5 riding on the guiding wire. After exact positioning of the elongate body 8 in the coronary sinus 5, as illustrated in Fig. 8 where the mitral valve 19 is shown having a central gap 20, the cover sheet 11 is retracted exposing the elongate body 8 within the coronary sinus 5. This manoeuvre allows the hooks 10 on the elongate body 8 to dig into the walls of the coronary sinus 5 and into the heart. The elongate body 8 is still locked on to the stabilising instrument 12 such that the hooks 10 engage the walls of the coronary sinus 5 in the stretched or extended state of the elongate body 8.

A catheter 21, shown in Fig. 6, is pushed forward on the guiding wire and the rod 15 for releasing the elongate body 8 from the locking means 16 by pressing the spring blades 18 towards the rod 15. This movement releases the knobs 17 as well as the arms 13 from engagement with the elongate body 8 which contracts as illustrated in Fig. 9 and as a result bends towards the mitral valve annulus 6 moving the posterior part thereof forward (shown by arrows in Fig. 9). This movement reduces the circumference of the mitral valve annulus 6 and thereby closes the central gap 20.

Fig. 7 illustrates a part of an arrangement of the wires 9 and the hooks 10 along a peripheral part of the elongate body 8, whereby the elongate body 8 will be asymmetrically contracted resulting in a bending thereof when interconnecting parts 22 of at least some of the hooks 10 are shortened to an original shape.

Figs 10 and 11 illustrate an alternative embodiment of an elongate body 8', which is a solid wire in the

shape of an open U-shaped ring that will engage the wall of the coronary sinus 5 most adjacent to the mitral valve annulus 6 when inserted into the coronary sinus 5. The elongate body 8' consists of a memory metal material which when reverting to its original shape will bend as illustrated in Fig. 11. The return of the open ring 8' to its original shape may be initiated in several ways, as is obvious to the man skilled in the art.

The third embodiment of the elongate body 8", illustrated in Figs 12 and 13, comprises three stent sections 23-25 positioned at one end of the elongate body 8", at the middle thereof and at the other end of the elongate body 8", respectively. These stent sections 23-25 may be positioned in the coronary sinus 5 as illustrated by conventional means, such that their positions are fixed. They are connected by wires 26, 27, which may be manoeuvred from outside the vein system such that the distances between the adjacent stent sections 23, 24 and 24, 25 are reduced. More specifically, these distances are reduced asymmetrically, i.e. more on the side of coronary sinus 5 most adjacent to the posterior part of the mitral valve annulus 6. Thereby, the elongate body 8" is bent, as illustrated in Fig. 13, and presses the coronary sinus 5 against the mitral valve annulus 6 closing the gap 20.

Concludingly, the present invention provides a device placed in the coronary sinus, designed to reduce the dilatation of the mitral annulus. This device is at a distance from the attachment of the posterior leaflet that does not much exceed the distance at which present annuloplasty rings are placed by open surgery techniques, and the coronary sinus is along its entire course large enough to hold such a device. The device could be positioned by catheter technique or any other adequate technique and offers a safer alternative to the current open surgery methods. The device could be designed or heparincoated so as to avoid thrombosis in the coronary

sinus, thus reducing the need for aspirin, ticlopedine or anticoagulant therapy.

It is to be understood that modifications of the above-described device and method can be made by people skilled in the art without departing from the spirit and scope of the invention.

CLAIMS

1. A device for treatment of mitral annulus dilatation, comprising an elongate body (8; 8'; 8") having such dimensions as to be insertable into the coronary sinus (5) and having two states, in a first of which the elongate body (8; 8'; 8") has a shape that is adaptable to the shape of the coronary sinus (5), and to the second of which the elongate body (8; 8'; 8") is transferable from the said first state assuming a reduced radius of curvature, whereby the radius of curvature of the coronary sinus (5) is reduced as well as the circumference of the mitral valve annulus (6), when the elongate body (8; 8'; 8") is positioned in the coronary sinus (5).

2. A device according to claim 1, further comprising means (9; 22; 26, 27) for the transfer of the elongate body (8; 8") to the second state by bending and shortening it from a larger radius of curvature to a smaller radius of curvature.

3. A device according to claim 2, wherein said transfer means (9; 22; 26, 27) comprises means for bending and shortening the elongate body (8) by a contraction thereof.

4. A device according to claim 1, wherein the elongate body (8; 8') comprises a memory material providing the transfer to the second state.

5. A device according to claim 1 or 2, wherein the elongate body (8) comprises a stent.

6. A device according to claim 2, wherein the elongate body (8") comprises several stent sections (23-25) and said bending means (9; 22; 26, 27) comprises wires (26, 27) for shortening the distance between the stent sections.

7. A method of reducing the circumference of the mitral valve annulus, comprising inserting an elongate body (8; 8'; 8") into the coronary sinus (5) in the vicinity of the posterior leaflet (2) of the mitral

valve, and providing a bending and shortening of the elongate body (8; 8'; 8") when positioned in the coronary sinus (5) so as to reduce the curvature of the coronary sinus (5) and thereby reduce the circumference of the mitral valve annulus (6).

8. A method according to claim 7, wherein said bending and shortening of the elongate body (8; 8") is provided by a contraction thereof.

9. A method according to claim 7 or 8, wherein a memory material is used in the elongate body (8') for providing the transfer to the second state.

10. A method according to claim 7 or 8, wherein the elongate body (8") is made from several stent sections (23-25) and wires (26, 27) are used for shortening the distance between the stent sections (23-25) in order to bend the elongate body (8").

ABSTRACT

A device for treatment of mitral annulus dilatation comprises an elongate body having two states. In a first of these states the elongate body is insertable into the coronary sinus and has a shape adapting to the shape of the coronary sinus. When positioned in the coronary sinus, the elongate body is transferable to the second state assuming a reduced radius of curvature, whereby the radius of curvature of the coronary sinus and the radius of curvature as well as the circumference of the mitral annulus is reduced.



Fig. 1



Fig. 2



Fig. 3



Fig. 4



Fig. 5



Fig. 6



Fig. 7



Fig. 8



Fig. 9



Fig. 10



Fig. 11



Fig. 12



Fig. 13

Page 1 of 2 Pages [X] Original [ ] Substitute [ ] Supplemental Atty. Docket: 1001363-000102

Combined Declaration for Patent Application and Power of Attorney

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and that I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

DEVICE AND METHOD FOR TREATMENT OF MITRAL INSUFFICIENCY

the specification of which (check one)

[ ] is attached hereto;

[ ] was filed in the United States under 35 U.S.C. §111 on _____, as U.S. Appln. No. _____*; or

[X] was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international (PCT) application, PCT/SE00/01369 filed 28.06.2000, entry requested on _____*; national stage application received U.S. Appln. No. _____*; §371/§102(e) date _____* (* if known)

and was amended on _____ (if applicable).

(Include dates of amendments under PCT Art. 19 and 34 if PCT)

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; and I acknowledge the duty to disclose to the Patent and Trademark Office (PTO) all information known by me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §§ 119 and 365 of any prior foreign application(s) for patent or inventor's certificate, or prior PCT application(s) designating a country other than the U.S., listed below with the "Yes" box checked and have also identified below any such application having a filing date before that of the application on which priority is claimed:

9902455-6 (Number)	Sweden (Country)	29/06/1999 (Day Month Year Filed)	[X] YES	[ ] NO
_____ (Number)	_____ (Country)	_____ (Day Month Year Filed)	[ ] YES	[ ] NO

I hereby claim the benefit under 35 U.S.C. §120 of any prior U.S. non-provisional application(s) or prior PCT application(s) designating the U.S. listed below, or under §119(e) of any prior U.S. provisional applications listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in such U.S. or PCT application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the PTO all information as defined in 37 C.F.R. §1.56(a) which occurred between the filing date of the prior application and the national filing date of this application:

_____ (Application No.)	_____ (Day Month Year Filed)	_____ (Status: patented, pending, abandoned)
_____ (Application No.)	_____ (Day Month Year Filed)	_____ (Status: patented, pending, abandoned)
_____ (Application No.)	_____ (Day Month Year Filed)	_____ (Status: patented, pending, abandoned)

As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

All of the practitioners associated with Customer Number 001444

Direct all correspondence to the address associated with **Customer Number 001444**; i.e.,

BROWDY AND NEIMARK, P.L.L.C.
624 Ninth Street, N.W.
Washington, D.C. 20001-5303
(202) 628-5197

The undersigned hereby authorizes the U.S. Attorneys or Agents appointed herein to accept and follow instructions from AWAPATENT AB as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. Attorneys or Agents and the undersigned. In the event of a change of the persons from whom instructions may be taken, the U.S. Attorneys or Agents appointed herein will be so notified by the undersigned.

Atty. Docket: 10010563-0P0102

Title: DEVICE AND METHOD FOR TREATMENT OF MITRAL INSUFFICIENCY

U.S. Application filed _____, Serial No. _____

PCT Application filed _____, Serial No. _____

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

100

FULL NAME OF FIRST INVENTOR	INVENTOR'S SIGNATURE	DATE
SOLEM, Jan Otto		
RESIDENT		CITIZENSHIP
Stetten, Switzerland CHX		Norwegian
POST OFFICE ADDRESS		
Wallenrutistrasse 14, CH-8234 STETTEN, Switzerland		

200

FULL NAME OF SECOND JOINT INVENTOR	INVENTOR'S SIGNATURE	DATE
KIMBLAD, Per Ola		
RESIDENT		CITIZENSHIP
Lund Sweden SEX		Swedish
POST OFFICE ADDRESS		
Saturnusgatan 9, SE-224 57 LUND, Sweden		

FULL NAME OF THIRD JOINT INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENT		CITIZENSHIP
POST OFFICE ADDRESS		

FULL NAME OF FOURTH JOINT INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENT		CITIZENSHIP
POST OFFICE ADDRESS		

FULL NAME OF FIFTH JOINT INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENT		CITIZENSHIP
POST OFFICE ADDRESS		

FULL NAME OF SIXTH JOINT INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENT		CITIZENSHIP
POST OFFICE ADDRESS		

FULL NAME OF SEVENTH JOINT INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENT		CITIZENSHIP
POST OFFICE ADDRESS		

ALL INVENTORS MUST REVIEW APPLICATION AND DECLARATION BEFORE SIGNING. ALL ALTERATIONS MUST BE INITIALED AND DATED BY ALL INVENTORS PRIOR TO EXECUTION. NO ALTERATIONS CAN BE MADE AFTER THE DECLARATION IS SIGNED. ALL PAGES OF DECLARATION MUST BE SEEN BY ALL INVENTORS.